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Introduction
Human papilloma virus (HPV) is one of the most common sexually transmitted infections worldwide, with an estimated global prevalence of 11.7% in women and 20% in men. 1, 2 Starting in fall 2012, all provinces and territories in Canada implemented school-based programs for girls ranging from grade 4 to 8, with catchup doses available in some provinces for girls younger than 18 years. As new evidence emerges on the benefit of vaccinating boys as well as girls, some provinces have started funding vaccination of school-aged boys as well (Table 1) . This review will summarize some of the background, evidence and controversies surrounding the vaccine (see Table 2 for terminology used in this article.)
Virus description
HPV is a nonenveloped double-stranded DNA virus that infects the epithelium through direct epithelial-to-epithelial contact such as oral-genital or genital-genital contact or vertically from mother to infant. More than 170 HPV subtypes have been identified, of which approximately 40 affect the anogenital area (including the anus, cervix, vulva, vagina and penis). The remaining HPV types may affect the oropharyngeal area or have unknown roles. The 40 genotypes affecting the anogenital area are categorized based on their associated risk with cervical cancer. Highrisk genotypes (including types 16, 18, 31, 33, 45, 52 and 58) have the potential for oncogenesis, whereas low-risk genotypes (including types 6 and 11) may cause benign cervical cell changes or genital warts. 2, 19, 20, 21 Epidemiology Globally, HPV prevalence in women ranges from 2% to 44%, with the highest risk occurring within 5 to 10 years of sexual debut. Canadian prevalence data to date show that overall prevalence of HPV infection in women aged 13 to 86 years is 17%. 19 High-risk HPV types are more predominant in women younger than 25 years, whereas low-risk and uncategorized HPV types are more common in women older than 55 years. 19, 20, 22 While Canadian prevalence in men is unknown, the worldwide male prevalence ranges up to 73%, with HPV type 16, a high-risk type, being most common. Unlike in women, there is no association between age and incidence in men. 19, 20, 22 While most HPV infections are self-limiting and cleared within 24 months, some infections cause genital warts or progress to malignancy. HPV infection is associated with 5.2% of all cancers worldwide. 19, 20, 21 In women, cervical cancer is the second most common malignancy after breast cancer, associated with approximately 91% of high-risk HPV subtypes. 19 Of these highrisk types, 16 and 18 are associated with 67% of cervical cancers in North America. [19] [20] [21] [22] [23] In men, HPV infection is associated with anal, penile, oropharyngeal and oral cancers. 19, 22 Similar to women, several HPV-associated cancers in males can be attributed to types 16 and 18. 19, 21 Several risk factors have been identified as predictors of HPV infection (Table 3) .
Frequently asked questions about HPV vaccination
Although the HPV vaccine has been available for almost a decade, there are still many clinical review misconceptions and questions regarding both HPV disease and vaccination. Pharmacists are in an excellent position to answer these questions for their patients.
What is the relationship between HPV infection and cancer?
While most HPV infections are asymptomatic, some infections may progress to genital warts, cervical neoplasias or a variety of cancers, including cervical, anal, penile and oropharyngeal. 20 The progression from infection to malignancy is not fully understood.
Asymptomatic HPV infections are not treated even if detected. However, anogenital warts, precancers and cancer, which are sequelae of HPV infection, require treatment. A Canadian study found that the average cost of treatment per episode of anogenital warts is $190 (in 2012 dollars), and each episode lasts 76 and 67 days in males and females, respectively. 24, 25 Cervical cancer may necessitate the need for removal of the cervix and may result in death. Progression to anal cancer may require surgery, radiation therapy and/or chemotherapy. Although the vast majority of HPV infections are cleared, individuals whose infections progress to anogenital warts or malignancy require repeated treatments, leading to stress for the patient as well as significant health care costs. 22, 24, 26 What do the current marketed HPV vaccines protect against? Three HPV vaccines are currently available on the Canadian market: Gardasil (HPV4; Merck Canada), Gardasil 9 (HPV9; Merck Canada) and Cervarix (HPV2; GlaxoSmithKline). Gardasil 9, the newest vaccine for HPV, was approved by Health Canada in 2015. Gardasil (HPV4) provides protection against HPV types 6/11/16/18, Gardasil 9 (HPV9) provides protection against HPV types 6/11/16/18/31/33/45/52/58 and Cervarix (HPV2) provides protection against HPV types 16/18. See Table 4 for Health Canada-labelled indications.
What is the effectiveness of the HPV vaccine in females?
Efficacy trials used precancer primary endpoints given the long time frame between infection and development of cancer. 20, 21, 29 Cervical intraepithelial neoplasia (CIN) 2/3 or adenocarcinoma in situ (AIS) are surrogate markers for cervical cancer; VaIN2/3, VIN2/3 and AIN2/3 are surrogate markers for vaginal, vulvar and anal cancers (Appendix 1, available in the online version of the article).
HPV9 used a combined endpoint of highgrade cervical, vulvar and vaginal disease, as well as a combined endpoint of CIN and AIS instead of assessing the individual endpoints studied in HPV2 and HPV4 studies. In addition, efficacy rates in HPV9 were reported as person-years, which makes it difficult to directly compare with HPV2/4 studies. Despite these differences in study methodology, HPV9 was shown to be noninferior to HPV4 and has consequently received the same indications as HPV4.
Cervical cancer. Efficacy trials for HPV4 have demonstrated that vaccination reduces CIN2/3 and AIS by 45.1% and 60%, respectively, within a 13-year follow-up period, 20, 21, 29 whereas HPV2 efficacy trials demonstrate reduction in CIN2/3 and AIS by 45.7% and 70%, respectively (Appendix 1). Considering that the time from infection to development of cervical cancer may take upwards of decades, ongoing surveillance of the HPV-vaccinated population by Health Canada and other organizations is necessary to determine vaccine efficacy against cervical cancer. 20, 21 The Public Health Agency of Canada continues to take an active role in ongoing surveillance in HPV vaccination and disease outcomes through various surveys and partnerships. 24, 28 Anal cancer. Similar to cervical cancer, vaccination is presumed to prevent anal cancer by reducing the incidence of HPV infection
Knowledge Into PractIce
• Because of the impact of human papilloma virus (HPV) infection, addressing the controversies surrounding HPV vaccination is an important public health initiative. • there are 3 HPV vaccinations available that protect against HPV viruses that can lead to various malignancies (e.g., cervical, anal, penile). • all provinces have publicly funded vaccination campaigns for school-aged girls and boys, except Saskatchewan, newfoundland, new Brunswick, Yukon territory, northwest territories and nunavut, who fund campaigns for girls only. efficacy based on clinical studies shows a reduction in cervical cancer of 45%, anal cancer of 54% and anogenital warts of 62%. • the HPV vaccines are extremely well tolerated and are not associated with increased sexual activity or risk.
clinical review (especially HPV 16/18) in clinical trials involving men (Appendix 2, available in the online version of the article). While Health Canada has approved HPV4 and HPV9 for anal cancer prevention in women, approval was based on efficacy data in men because risk factors for HPV anal cancer and progression of anal cancer in both genders are presumed to be similar. 20, 29 HPV vaccination reduces the risk of anal cancer by 54.2% (Appendix 2). Although HPV2 studies included the outcome of reduction of anal infection with vaccination, it was not granted this indication by Health Canada because the primary endpoint was the presence of HPV DNA and not precancerous cells. As such, only HPV4/HPV9 should be used for the indication of anal cancer prevention.
Anogenital warts. Compared with cancer, reductions are much higher for genital warts because they are more prevalent and progress more rapidly than anal cancer. 29 HPV4 and HPV9, the only HPV vaccines approved for anogenital warts, reduce the incidence of genital warts by 62% over a 3-year period.
What is the effectiveness in women who are already infected?
In individuals with prevalent cervicovaginal infection or low-grade disease, disease course clinical review is not affected by HPV vaccination. 29 Women are not normally screened for infection prior to vaccination. However, women should be encouraged to continue regular cervical cancer screening with Pap smears even after being vaccinated.
No difference was observed in the time to clearance of established infection between those who received HPV2 and controls. In those with established infection with HPV16/18, there is no difference in the rate of progression to CIN2/3 in those who received HPV4 and controls. 29 For females with previous history of Pap abnormalities, including cervical cancer and/ or genital warts, HPV4 or HPV2 is still recommended (Grade B), as they could still benefit from protection against virus types to which they were not previously exposed. 19 Although Health Canada has not made specific recommendations regarding HPV9 in this situation, its noninferiority to HPV4 likely makes it a reasonable option as well.
What is the role of vaccination in females older than 26 years? Women older than 26 years continue to be at risk of exposure to HPV. After the initial peak of HPV infection risk 5 to 10 years after sexual Table 3 risk factors for human papilloma virus infections 19, 20 Females Males clinical review debut, a second peak of prevalence occurs after 45 years. Therefore, vaccinating women older than 26 years may still be beneficial by protecting against new HPV types. 19 As noted in Table  4 , studies included women up to age 45 years. Use of the vaccine beyond this age should consider patient preference and the risks of continued exposure.
What is the role of vaccination in males?
Clinical efficacy trials for HPV4 have demonstrated a reduction in the incidence of anogenital warts and AIN2/3, a surrogate marker of anal cancer, by 65.5% and 54.2%, respectively (Appendix 2). Efficacy in the prevention of penile, perineal and perianal intraepithelial neoplasias could not be evaluated, as there were too few cases observed in the studies. 19, 20, 29 However, efficacy for a combined endpoint of external genital lesions, which includes genital warts, penile, perineal and perineal neoplasias, has been reported (Appendix 2). Considering the rapid progression and higher prevalence of genital warts, the efficacy of this combined endpoint may be driven by the reduction in genital warts. As such, HPV4 has been approved by Health Canada for the indication of anal cancer and genital wart prevention. While HPV9 was not studied in males, it was demonstrated to be noninferior to HPV4 in females. With these findings, HPV9 has received the same Health Canada indication in males. HPV2 has not been investigated in males and does not have a role in males.
As in females, there is no role for vaccination of males to protect against HPV types to which they have established HPV infection. 4 
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What is the role of vaccination in males older than 26 years?
The Public Health Agency of Canada (PHAC) suggests considering vaccination in males who have sex with other males (MSM) older than 26 years given the high disease burden (e.g., external genital warts) in that population. However, this recommendation is controversial, given the lack of published data supporting its efficacy in men older than 26 years of age. 19, 20 In clinical trials, the oldest man included was 26 years. Therefore, it is suggested to consider patient risk factors (Table 3) , patient-specific factors (e.g., ability to afford vaccine, adherence to administration schedule) and patient preference.
What is HPV2's place in therapy?
Aside from the differences in HPV type targets and Health Canada indications, HPV4/ HPV9 and HPV2 also have formulation differences. HPV4/HPV9 use a simple aluminum salt adjuvant to increase immunogenicity. However, HPV2 contains a more complex adjuvant (AS04) composed of monophosphoryl lipid A and an aluminum salt. AS04 is a unique adjuvant designed to target the activation of innate and adaptive immune responses. 28 In one study that compared the immunogenicity of HPV2 and HPV4, HPV2 resulted in higher levels of antibodies for HPV16/18 than HPV4. This difference in antibody levels was attributed to the difference in adjuvant systems between the 2 products. 29 However, it is important to keep in mind that the correlation between antibody titres and immunity has not been established. 20, 29 All publicly funded Canadian HPV vaccine programs currently use HPV4. However, in most Canadian jurisdictions, HPV2 is less expensive than HPV4, so it might be an option for patients who do not qualify for public funding.
Considering the lack of understanding regarding the association between HPV antibody titres and immune response, the choice of HPV vaccine should balance patient-specific factors (such as cost, the perceived importance of genital wart protection and gender 3 ) with current evidence.
Has HPV vaccination had any impact on HPV prevalence?
There is a scarcity of Canadian data on disease outcome, which may be due to the relatively recent induction of public vaccination programs in certain jurisdictions and the lack of a registrybased data system. 19 Although all Canadian provinces and territories have public HPV vaccination programs, reported HPV vaccine uptake varies. Based on data up to June 2013, HPV vaccine uptake ranges from 40% in Manitoba to 90% in Newfoundland. 19 US data on postvaccination HPV prevalence is promising. HPV4 (HPV types 6/11/16/18) prevalence in the United States prior to the introduction of HPV vaccine was compared with prevalence following the introduction of vaccine in 2006. Prior to HPV vaccination, HPV prevalence in 14-to 19-year-olds and 20-to 25-year-olds was 11.5% and 18.5%, respectively. Following introduction of HPV vaccination programs, HPV prevalence decreased to 4.3% (adjusted relative risk = 7.2%) and 12.1% (adjusted relative risk = 6.4%), respectively. 30 
How many doses of vaccine are required for adequate protection?
To date, immunogenicity studies have demonstrated that antibody titres in 10-to 14-year-olds who received 2 doses spaced 6 months apart are similar to 15-to 25-year-olds who received 3 doses with an optimized 3-dose schedule (Appendix 3, available in the online version of the article). [31] [32] [33] As such, the World Health
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• Étant donné les répercussions de l'infection par le VPH, l'initiative de santé publique visant à désamorcer les controverses liées au vaccin contre le VPH revêt une grande importance. • les trois vaccins contre le VPH qui sont actuellement disponibles offrent une protection contre des VPH responsables de diverses affections malignes (cancers du col de l'utérus, de l'anus et du pénis). • toutes les provinces ont financé des campagnes de vaccination pour les femmes et les hommes d'âge scolaire, à l'exception de la Saskatchewan, de terre-neuve, du nouveau-Brunswick, du Yukon, des territoires du nord-ouest et du nunavut, qui ont financé une campagne visant seulement les femmes. Pour ce qui est de l'efficacité, les études cliniques ont démontré une réduction du cancer du col de l'utérus de 45 %, du cancer de l'anus de 54 % et des condylomes anogénitaux de 62 %. • les vaccins contre le VPH sont extrêmement bien tolérés et ne sont pas associés à une augmentation de l'activité sexuelle ou à des risques.
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Organization (WHO) endorses the use of the 2-dose schedule for 9-to 13-year-old girls to improve adherence and to reduce costs associated with vaccination based upon immunogenicity studies. 32 However, it is important to note that the relationship between antibody titre and immune response to HPV has not yet been established. Consistent with the existing literature and WHO recommendations, the vast majority of provinces provide 2 doses to individuals 14 years of age and younger (Appendix 3). In individuals older than 14 years, the 3-dose schedule is recommended. However, it is important to note that HPV9 has not been studied using the 2-dose schedule. 34 What is the duration of vaccine protection? Vaccination appears to provide protection for at least 8 years, given that HPV4-and HPV2-vaccinated cohorts have been followed 9 years and 8.4 years, respectively. 19, 31, 33 As such, no booster dose is required to date.
The duration of protection for HPV9 has not yet been established. 22, 35 PHAC continues to take an active role in monitoring the relationship between disease outcomes and HPV vaccination in partnership with vaccine manufacturers. 19 What is the current HPV vaccination schedule in Canada and who receives coverage?
See Table 1 .
Safety
What are some acute adverse effects associated with provision of HPV vaccine? Acute adverse effects associated with HPV vaccination are similar to other vaccines ( Table 5) .
Are there any long-term or serious adverse effects associated with provision of HPV vaccine?
As with all vaccinations, there is a potential risk for anaphylaxis with provision of the HPV vaccine. However, surveillance to date has not identified an association between HPV vaccine and disease states, such as Guillain-Barré syndrome or multiple sclerosis. 19, 31, 37 A common misconception that should be clarified is that HPV vaccination in grade school children will result in increased sexual activity. 38, 39 An observational study followed a cohort of grade 8 Ontario girls and found that HPV vaccination does not have a significant effect on promiscuity, as defined by pregnancy and non-HPV-related sexually transmitted infections, in grades 10 to 12. 38 Pharmacists need to address misconceptions and concerns to ensure that parents are able to make an informed decision regarding vaccination. 38 Following a review of the available literature and reports regarding vaccine safety in 2015, Health Canada has not found any new safety issues associated with the provision of HPV4. 19 Table 5 Potential acute adverse effects associated with HPV4 and HPV2 vaccines 19, 25, [27] [28] [29] 36, 37 Potential acute adverse effects 
Percentage of patients reporting adverse event in clinical trials

Cost-effectiveness
Is it cost-effective to vaccinate everyone? Several cost-benefit analyses demonstrate the cost-effectiveness of vaccinating girls younger than 12 years. However, it is suggested that the cost-effectiveness of vaccination decreases with increasing age. 20, 29, 40 Nevertheless, other models suggest that vaccination of females into their 20s may still be cost-effective. As such, a specific age at which it is no longer cost-effective to vaccinate has not been established. 20 Vaccination is costeffective to less than 26 years, which is consistent with most provinces. Cost-effectiveness in males is less established than in females. 20, 29, 40 Through herd immunity, male vaccination is more favourable when there are lower rates of female vaccination. Similar to females, cost-effectiveness of male vaccination decreases with increasing age. 29 Conversely, evidence suggests that vaccination of MSM until 26 years of age is cost-effective. 29 Most provinces and territories have provided a publicly funded vaccine for specific age groups who receive the greatest cost-benefit. Ultimately, patient preference is the determining factor in HPV vaccination.
Pharmacist's role
The majority of parents would like to be provided with information that will allow them to make an informed decision regarding the HPV vaccination for themselves or their child. 41 Pharmacists' accessibility positions them to meet this demand. It is important for pharmacists to provide accurate information regarding HPV infection and its consequences, the risks and benefits of vaccination, duration of protection and vaccination schedules. Moreover, pharmacists should address misconceptions and help parents to overcome barriers ( Table 6 ) to HPV vaccine uptake. 41 Pharmacists should also educate patients regarding vaccination schedules. Vaccination should occur in a timely manner and according to the vaccination schedule to ensure prevention of infection and cancer.
Pharmacists should be willing to advocate for the vaccination of children and adolescents prior to sexual debut to ensure that patients may have the greatest level of protection against HPV infection, thereby minimizing risk of cancer. Moreover, pharmacists should be willing to advocate for vaccination of both males and females. Ultimately, pharmacists should recommend in favour of HPV vaccination to minimize infection and improve public health outcomes and facilitate the HPV vaccine series while taking patient values into account. 41
Conclusion
HPV is the most common sexually transmitted infection, and HPV types 6, 11, 16 and 18 are associated with cervical, vulvar and vaginal cancers in women, along with anal cancer and anogenital warts in both males and females. HPV vaccines (HPV9, HPV4 and HPV2) have shown efficacy in the prevention of HPV infections in certain populations. Further research into the role of HPV vaccination beyond 26 years of age and need for booster doses is required. HPV vaccination plays an important role in public health. As such, pharmacists can advocate for vaccination and provide information as well as access to individuals seeking HPV vaccination. ■ Table 6 a list of societal and behavioural barriers to human papilloma virus (HPV) vaccine uptake 31, 41, 42 • cost • Health care infrastructure (access to vaccine and routine medical care) • Patient, parent, provider education  Perceived susceptibility of patient to HPV infection  Perceived benefits  Perceived safety concerns  Perceived impact on sexual behaviour • cultural acceptance (media coverage, social norms) • Public policy and vaccine delivery (e.g., provided in canadian schools) clinical review 
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